Zhou et al. used macrophage-derived exosome-mimicking nanovesicles (EMVs) as a nanoplatform for delivering the CD73 inhibitor (AB680) and programmed cell death ligand 1 (PD-L1) inhibitors in a mouse model of bladder cancer. Here, CD274 is linked to urinary bladder cancer.